Amgen Stock (NASDAQ:AMGN)
Previous Close
$349.92
52W Range
$261.43 - $391.29
50D Avg
$359.42
200D Avg
$316.58
Market Cap
$187.49B
Avg Vol (3M)
$2.74M
Beta
0.42
Div Yield
$9.66 (2.78%)
AMGN Company Profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 25 | Dec 24 | Dec 23 |
|---|---|---|---|
| EVENITY | $2.10B | $1.56B | - |
| KRYSTEXXA | $1.34B | $1.19B | $272.00M |
| Nplate | $1.52B | $1.46B | $1.48B |
| TEZSPIRE | $1.48B | $972.00M | - |
| TEPEZZA | $1.90B | $1.85B | $448.00M |
| Repatha | $3.02B | - | - |
| Prolia | $4.41B | $4.37B | $4.05B |
| Product and Service, Other | $1.60B | $1.40B | $1.28B |
| Other Products | $7.26B | $5.63B | $5.26B |
| Otezla | $2.27B | $2.13B | $2.19B |
| XGEVA | $2.08B | $2.23B | $2.11B |
| Vectibix | $1.18B | $1.04B | $984.00M |
| Aranesp | $1.39B | $1.34B | $1.36B |
| BLINCYTO | $1.56B | $1.22B | $861.00M |
| ENBREL | $2.23B | $3.32B | $3.70B |
| Repatha (evolocumab) | - | $2.22B | $1.64B |
| Kyprolis | - | $1.50B | $1.40B |
| Evenity | - | - | $1.16B |
Fiscal year ends in Dec 25 | Currency in USD